RxDoctor Payments DataLook up a doctor →

Arabinda Chatterjee, MD

Family Medicine · N. Grosvenordale, CTNPI 1043278674

Payments from drug & device makers

$14,723in general payments, 2019–2025

Across 412 payments — averaging $35.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$797
  • Phathom Pharmaceuticals, Inc.$711
  • plus $7K from 35 others

What the payments were for

  • Food & beverage$14,56799%
  • Education$1561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,723 in reported general payments places this provider in the 95th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$34,915
Medicare patients
71
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$118,920
EliquisApixaban53$58,542
OzempicSemaglutide23$36,206
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$25,610
TrulicityDulaglutide14$12,179
Gabapentin123$3,630
Rosuvastatin Calcium261$3,253
Raloxifene Hcl68$2,623
Famotidine176$2,617
Atorvastatin Calcium333$2,594
SynthroidLevothyroxine Sodium22$2,522
Amlodipine Besylate303$2,129
Wixela InhubFluticasone Propion/Salmeterol22$1,851
Duloxetine Hcl64$1,838
Montelukast Sodium159$1,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$797$118,920101 claims
PfizerEliquis$245$58,54253 claims
Novo NordiskOzempic$1,065$36,20623 claims
GSKTrelegy Ellipta$1,346$25,61014 claims
Lilly USA, LLCTrulicity$631$12,17914 claims
AbbVieSynthroid$1,848$2,52222 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$1,548194 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family medicine providers in Connecticut.

Other family medicine in N. Grosvenordale

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →